Patient-Reported Outcomes in RLBP1 Retinal Dystrophy: Longitudinal Assessment in a Prospective Natural History Study
Translational Vision Science & Technology · 2024
DOI: 10.1167/tvst.13.11.16 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2024. Verfasst von James Whelan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Memorial University of Newfoundland, St. John's, Newfoundland, Canada. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Retinal Dystrophies, Visual Acuity. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the performance of two non-disease-specific patient-reported outcome (PRO) instruments, the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and the Low Luminance Questionnaire (LLQ), in patients with retinaldehyde-binding protein 1 retinal dystrophy (RLBP1 RD).
Methods
PROs were assessed using the VFQ-25 and LLQ. Rasch analysis was conducted to estimate person and item measures of the VFQ-25 and LLQ questionnaires to determine the association between the two PROs. In addition, the association between these two instruments and their correlations to weighted measures of visual function and disease progression were analyzed in this three-year PRO-focused sub-study of a five-year prospective natural history study.
Results
Forty-two patients participated, with most of them having completed at least two PRO follow-up visits at least one year apart. The mean VFQ-25 scores were lowest for distance activities (39.2-49.0) and peripheral vision (37.5-52.4), with mean LLQ subscale scores generally low (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
- Clinical Sciences/Ophthalmology, University of Umeå, Umeå, Sweden.
- BioMedical Research, Cambridge, MA, USA.
- Novartis Pharma AG, Basel, Switzerland.
- Beijing Novartis Pharmaceuticals Corporation, Shanghai, China.
- BioMedical Research, East Hanover, NJ, USA.
Zitieren
APA
Whelan, J., Green, J., Burstedt, M., Greco, E., Ni, X., Spera, C., Mullins, A., Deslandes, J. Y., Su, Z., Wald, M., Grosskreutz, C. L., Normand, G., Charil, A., Lu, D., Stasi, K., & Holopigian, K. (2024). Patient-Reported Outcomes in RLBP1 Retinal Dystrophy: Longitudinal Assessment in a Prospective Natural History Study. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.13.11.16
Vancouver
Whelan J, Green J, Burstedt M, Greco E, Ni X, Spera C, et al. Patient-Reported Outcomes in RLBP1 Retinal Dystrophy: Longitudinal Assessment in a Prospective Natural History Study. Translational Vision Science & Technology. 2024. doi:10.1167/tvst.13.11.16
BibTeX
@article{Whelan2024,
author = {Whelan, James and Green, Jane and Burstedt, Marie and Greco, Erin and Ni, Xiao and Spera, Claudio and Mullins, Anmol and Deslandes, Jean-Yves and Su, Zhenzhong and Wald, Michael and Grosskreutz, Cynthia L and Normand, Guillaume and Charil, Arnaud and Lu, Darlene and Stasi, Kalliopi and Holopigian, Karen},
title = {Patient-Reported Outcomes in RLBP1 Retinal Dystrophy: Longitudinal Assessment in a Prospective Natural History Study},
journal = {Translational Vision Science & Technology},
year = {2024},
doi = {10.1167/tvst.13.11.16}
}
EUVIMED